{
  "Symbol": "MRNA",
  "AssetType": "Common Stock",
  "Name": "Moderna Inc",
  "Description": "Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.",
  "CIK": "1682852",
  "Exchange": "NASDAQ",
  "Currency": "USD",
  "Country": "USA",
  "Sector": "LIFE SCIENCES",
  "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
  "Address": "200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US",
  "OfficialSite": "https://www.modernatx.com",
  "FiscalYearEnd": "December",
  "LatestQuarter": "2024-12-31",
  "MarketCapitalization": "9951676000",
  "EBITDA": "-3756000000",
  "PERatio": "None",
  "PEGRatio": "0",
  "BookValue": "28.24",
  "DividendPerShare": "None",
  "DividendYield": "None",
  "EPS": "-9.28",
  "RevenuePerShareTTM": "8.43",
  "ProfitMargin": "-1.1",
  "OperatingMarginTTM": "-1.29",
  "ReturnOnAssetsTTM": "-0.151",
  "ReturnOnEquityTTM": "-0.288",
  "RevenueTTM": "3236000000",
  "GrossProfitTTM": "-2771000064",
  "DilutedEPSTTM": "-9.28",
  "QuarterlyEarningsGrowthYOY": "-0.851",
  "QuarterlyRevenueGrowthYOY": "-0.656",
  "AnalystTargetPrice": "50.92",
  "AnalystRatingStrongBuy": "1",
  "AnalystRatingBuy": "5",
  "AnalystRatingHold": "17",
  "AnalystRatingSell": "1",
  "AnalystRatingStrongSell": "3",
  "TrailingPE": "-",
  "ForwardPE": "32.47",
  "PriceToSalesRatioTTM": "3.075",
  "PriceToBookRatio": "0.891",
  "EVToRevenue": "1.075",
  "EVToEBITDA": "4.641",
  "Beta": "2.233",
  "52WeekHigh": "170.47",
  "52WeekLow": "23.15",
  "50DayMovingAverage": "31.07",
  "200DayMovingAverage": "55.96",
  "SharesOutstanding": "386623000",
  "DividendDate": "None",
  "ExDividendDate": "None",
  "Last Updated": "2025-04-23 14:46:01",
  "Price_Day_1": 25.74,
  "Price_Day_2": 25.13,
  "Price_Day_3": 24.715,
  "Price_Day_4": 25.19,
  "Price_Day_5": 26.24,
  "Price_Day_6": 26.8,
  "Price_Day_7": 26.2,
  "Income_totalRevenue_Q1": "966000000",
  "Income_grossProfit_Q1": "227000000",
  "Income_netIncome_Q1": "-1120000000",
  "Income_totalRevenue_Q2": "1855000000",
  "Income_grossProfit_Q2": "1341000000",
  "Income_netIncome_Q2": "13000000",
  "Income_totalRevenue_Q3": "241000000",
  "Income_grossProfit_Q3": "85000000",
  "Income_netIncome_Q3": "-1279000000",
  "Income_totalRevenue_Q4": "167000000",
  "Income_grossProfit_Q4": "35000000",
  "Income_netIncome_Q4": "-1175000000",
  "Balance_totalAssets_Q1": "14142000000",
  "Balance_totalLiabilities_Q1": "3241000000",
  "Balance_totalShareholderEquity_Q1": "10901000000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q1": "1927000000",
  "Balance_totalAssets_Q2": "15803000000",
  "Balance_totalLiabilities_Q2": "3876000000",
  "Balance_totalShareholderEquity_Q2": "11927000000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q2": "1644000000",
  "Balance_totalAssets_Q3": "15680000000",
  "Balance_totalLiabilities_Q3": "3968000000",
  "Balance_totalShareholderEquity_Q3": "11712000000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q3": "2478000000",
  "Balance_totalAssets_Q4": "16729000000",
  "Balance_totalLiabilities_Q4": "3912000000",
  "Balance_totalShareholderEquity_Q4": "12817000000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q4": "2051000000",
  "Debt to Equity Ratio": 0.3,
  "Is Complete": true
}